Hematology and Oncology Book


CAR T-Cell Therapy

Aka: CAR T-Cell Therapy, CAR T Cell Therapy, Chimeric Antigen Receptor T Cell Therapy, Tisagenlecleucel, Axicabtagene ciloleucel
  1. See Also
    1. Targeted Cancer Therapy
    2. Monoclonal Antibody-Mediated Chemotherapy
    3. Immune Checkpoint Inhibitor
    4. CAR T-Cell Therapy
    5. Small Molecule Inhibitor-Mediated Chemotherapy
    6. Chemotherapy
  2. Mechanism
    1. Extraction of WBCs via Leukapheresis
      1. White Blood Cells (including T Cells) extracted from patient's blood and T Cells are concentrated
      2. White cells of interest for re-engineering
        1. Natural Killer Cells (NK cells)
        2. Lymphokine-activated Killer T Cells
        3. Cytotoxic T cells
        4. Dendritic Cells
    2. Reprogramming
      1. Synthesis of Gene encoding for chimeric Antigen receptor (CAR) that targets specific Antigen (along with cosignals)
      2. Manufacturing introduces into the T Cells, a CAR-encoded gene via viral vector
    3. Multiplication
      1. Engineered CAR T Cells are multiplied in a bioreactor
    4. Preparation with lymphodepletion
      1. Patient is administered Chemotherapy to suppress their own White Blood Cells
    5. Treatment
      1. Engineered CAR T Cells are infused into the patient
      2. T Cells recognize target Antigens and destroy cancer cells
        1. Sensitization to additional cancer cell components (cross-prime), providing additional cancer destruction
  3. Preparations: CD19 Cell Surface Targets
    1. Tisagenlecleucel
      1. B Cell Acute Lymphoblastic Leukemia
    2. Axicabtagene ciloleucel
      1. B Cell Lymphoma subtypes
  4. Adverse Effects
    1. See Cytokine Release Syndrome (CRS)
    2. Neurotoxicity
      1. Signs
        1. Headache
        2. Expressive Aphasia
        3. Confusion to Delirium
        4. Seziures (including nonconvulsive Status Epilepticus in 10% of cases)
        5. Cerebral edema
        6. Encephalopathy (CAR T Cell-related encephalopathy or CRES)
      2. Management
        1. Seizure Prophylaxis
        2. Corticosteroids may be more effective than Tocilizumab (see dosing under CRS as above)
    3. On-Target/Off Tumor Recognition
      1. T Cell attacks noncancerous cells displaying target Antigen
  5. References
    1. Jansson and Pallin (2020) Crit Dec Emerg Med 34(4): 19-28
    2. Santomasso (2019) Am Soc Clin Oncol Educ Book 39:433-444

You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree